Endoscopic lung volume reduction coil treatment in patients with very low FEV1: an observational study.

Abstract:

BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted to assess the effects and the safety of LVRC treatment in patients with very low FEV1. METHODS:The study was performed as a retrospective observational study in the Department of Respiratory Medicine at the University Medical Center Hamburg-Eppendorf on patients with very low FEV1, defined as an FEV1 ⩽ 20% of predicted at baseline in whom LVRC treatment was performed between 1 April 2012 and 28 February 2017. RESULTS:LVRC treatment was performed in 33 patients with very low FEV1. Of these, 45.5% were female and 54.5% were male. At baseline, mean FEV1 was 0.46 ± 0.12 liters (15 ± 3% of predicted), mean forced vital capacity (FVC) was 1.61 ± 0.62 liters (42 ± 13% of predicted), mean residual volume (RV) was 6.03 ± 0.81 liters (275 ± 51% of predicted) and 6-minute walk distance was 229 ± 102 m. Bilateral LVRC treatment was completed in 21 of these patients (63.6%). Bilateral LVRC treatment led to significant improvements in functional parameters with an increase in mean FEV1 from 0.44 ± 0.11 liters to 0.54 ± 0.12 liters ( p = 0.001), equivalent to a relative improvement of 24.5 ± 26.9%, an increase in mean FVC from 1.49 ± 0.54 liters to 1.84 ± 0.49 liters ( p = 0.001), a decrease in mean RV from 6.27 ± 0.83 liters to 5.83 ± 1.09 liters ( p = 0.004) and an improvement in 6-minute walk distance from 218 ± 91 m to 266 ± 96 m ( p = 0.01). There were no cases of respiratory failure requiring mechanical ventilation and no deaths. CONCLUSIONS:LVRC treatment was effective and safe in patients with very low FEV1.

journal_name

Ther Adv Respir Dis

authors

Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

doi

10.1177/1753466618760133

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

1753466618760133

eissn

1753-4658

issn

1753-4666

journal_volume

12

pub_type

杂志文章
  • The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study.

    abstract:BACKGROUND:Comorbidities probably contribute to the increased mortality observed among subjects with chronic obstructive pulmonary disease (COPD), but sex differences in the prognostic impact of comorbidities have rarely been evaluated in population-based studies. The aim of this study was to evaluate the impact of com...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466619860058

    authors: Sawalha S,Hedman L,Backman H,Stenfors N,Rönmark E,Lundbäck B,Lindberg A

    更新日期:2019-01-01 00:00:00

  • Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

    abstract::Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of ad...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618801167

    authors: Hida T

    更新日期:2018-01-01 00:00:00

  • Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial.

    abstract:BACKGROUND:Autologous blood is a novel, high-efficacy sclerosant for treatment of malignant pleural effusion (MPE), similar to tetracycline. There has been no comparative data between autologous blood and a worldwide sclerosant like talc. We aimed to compare the effectiveness of autologous blood versus talc pleurodesis...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1753466618816625

    authors: Keeratichananont W,Kaewdech A,Keeratichananont S

    更新日期:2018-01-01 00:00:00

  • Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

    abstract::Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816669662

    authors: Kappen JH,Durham SR,Veen HI,Shamji MH

    更新日期:2017-01-01 00:00:00

  • New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.

    abstract::Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618794133

    authors: Villanueva N,Bazhenova L

    更新日期:2018-01-01 00:00:00

  • Early predictors for mechanical ventilation in COVID-19 patients.

    abstract:OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620963017

    authors: Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

    更新日期:2020-01-01 00:00:00

  • Matrix metalloprotease polymorphisms are associated with gas transfer in alpha 1 antitrypsin deficiency.

    abstract:UNLABELLED:Alpha-1-antitrypsin deficiency [AATD] is associated with variable development of emphysema and other features of chronic obstructive pulmonary disease [COPD]. Matrix metalloproteinases [MMPs] are believed to be important in the pathophysiology of COPD, and may therefore confer susceptibility to this phenotyp...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465809102263

    authors: McAloon CJ,Wood AM,Gough SC,Stockley RA

    更新日期:2009-02-01 00:00:00

  • Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

    abstract::Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812459899

    authors: Hurley M,Smyth A

    更新日期:2012-12-01 00:00:00

  • Reclassifying severity after 48 hours could better predict mortality in acute respiratory distress syndrome.

    abstract:BACKGROUND:Disease severity may change in the first week after acute respiratory distress syndrome (ARDS) onset. The aim of this study was to evaluate whether the reclassification of disease severity after 48 h (i.e. day 3) of ARDS onset could help in predicting mortality and determine factors associated with ARDS pers...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620936877

    authors: Chiu LC,Lin SW,Liu PH,Chuang LP,Chang CH,Hung CY,Li SH,Lee CS,Wu HP,Huang CC,Li HH,Kao KC,Hu HC

    更新日期:2020-01-01 00:00:00

  • Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection.

    abstract::Background We wanted to determine the impact of combined Clinical Pulmonary Infection Score (CPIS) and a spot serum procalcitonin (PCT)-guided protocol to shorten the duration of antibiotic treatment in patients with ventilator-associated pneumonia (VAP), mainly caused by nonfermentative gram-negative bacilli (NF-GNB)...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466618760134

    authors: Wongsurakiat P,Tulatamakit S

    更新日期:2018-01-01 00:00:00

  • Beneficial role of vitamin D3 in the prevention of certain respiratory diseases.

    abstract::There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465813503029

    authors: Luong KV,Nguyen LT

    更新日期:2013-12-01 00:00:00

  • Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study.

    abstract:BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753466618778955

    authors: Arnitz R,Stein M,Bauer P,Lanthaler B,Jamnig H,Scholl-Bürgi S,Stempfl-Al-Jazrawi K,Ulmer H,Baumgartner B,Embacher S,Geisler S,Gostner JM,Müllinger B,Kälz B,Nagl M

    更新日期:2018-01-01 00:00:00

  • Use of dry powder inhalers in acute exacerbations of asthma and COPD.

    abstract::To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809103737

    authors: Selroos O,Borgström L,Ingelf J

    更新日期:2009-04-01 00:00:00

  • A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma.

    abstract:BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620981863

    authors: Xu L,Yi M,Tan Y,Yi Z,Zhang Y

    更新日期:2020-01-01 00:00:00

  • Surfactant protein D: a lung specific biomarker in COPD?

    abstract::A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808088903

    authors: Sin DD,Pahlavan PS,Man SF

    更新日期:2008-04-01 00:00:00

  • Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.

    abstract:AIMS:The Cough Severity Diary (CSD) was developed in accordance with the FDA guidance for patient-reported outcome measures and is focused on capturing the patient's perception of cough in terms of frequency, intensity, and disruption due to their cough. The measure includes a series of seven items asking patients to r...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620915155

    authors: Martin Nguyen A,Bacci E,Dicpinigaitis P,Vernon M

    更新日期:2020-01-01 00:00:00

  • Current approaches to pharmacotherapy for smoking cessation.

    abstract::It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809353768

    authors: Hudmon KS,Corelli RL,Prokhorov AV

    更新日期:2010-02-01 00:00:00

  • Therapeutic perspectives in bronchial vascular remodeling in COPD.

    abstract::COPD may be characterized by significant changes in airway mucosal blood vessels, which may contribute to bronchial airway remodeling. The airway wall is more vascularized in COPD patients than in healthy subjects, though this phenomenon is less evident than in asthmatic patients. The vascular mucosal changes in the a...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808092339

    authors: Zanini A,Chetta A,Olivieri D

    更新日期:2008-06-01 00:00:00

  • TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.

    abstract::Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe g...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466620926800

    authors: Chen XY,Yan BX,Man XY

    更新日期:2020-01-01 00:00:00

  • Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin.

    abstract:BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620905279

    authors: Akkerman-Nijland AM,Yousofi M,Rottier BL,Van der Vaart H,Burgerhof JGM,Frijlink HW,Touw DJ,Koppelman GH,Akkerman OW

    更新日期:2020-01-01 00:00:00

  • Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis.

    abstract:BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620935774

    authors: Enomoto N,Naoi H,Aono Y,Katsumata M,Horiike Y,Yasui H,Karayama M,Hozumi H,Suzuki Y,Furuhashi K,Fujisawa T,Inui N,Nakamura Y,Suda T

    更新日期:2020-01-01 00:00:00

  • Current best practice in pulmonary rehabilitation for chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812444712

    authors: de Blasio F,Polverino M

    更新日期:2012-08-01 00:00:00

  • Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma.

    abstract:OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465813476564

    authors: Scichilone N,Scalici V,Arrigo R,Bellia V

    更新日期:2013-08-01 00:00:00

  • Baseline history of patients using selexipag for pulmonary arterial hypertension.

    abstract:INTRODUCTION:Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466619843774

    authors: Highland KB,Hull M,Pruett J,Elliott C,Tsang Y,Drake W

    更新日期:2019-01-01 00:00:00

  • Experiences with treprostinil in the treatment of pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812455368

    authors: Stream AR,Bull TM

    更新日期:2012-10-01 00:00:00

  • Improving home oxygen therapy in patients with interstitial lung diseases: application of a noninvasive ventilation device.

    abstract:BACKGROUND:Proper adjustment of arterial oxygen saturation (SaO2) during daily activities in patients with interstitial lung disease (ILD) requiring long-term oxygen therapy is challenging. Given the multifactorial nature of the limited exercise tolerance in patients with ILDs, the isolated use of oxygen therapy may no...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620963027

    authors: Cuerpo S,Palomo M,Hernández-González F,Francesqui J,Albacar N,Hernández C,Blanco I,Embid C,Sellares J

    更新日期:2020-01-01 00:00:00

  • The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.

    abstract::In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465814530182

    authors: Steriade A,Seferian A,Jaïs X,Savale L,Jutant EM,Parent F,Sitbon O,Humbert M,Simonneau G,Montani D

    更新日期:2014-06-01 00:00:00

  • Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.

    abstract:OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753465813497527

    authors: Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

    更新日期:2013-10-01 00:00:00

  • An update on the use of indacaterol in patients with COPD.

    abstract::Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465810387810

    authors: Brienza NS,Amor-Carro O,Ramos-Barbón D

    更新日期:2011-02-01 00:00:00

  • Narrow-band imaging bronchoscopy in the detection of premalignant airway lesions: a meta-analysis of diagnostic test accuracy.

    abstract:OBJECTIVES:Both autofluorescence imaging bronchoscopy and narrow-band imaging have shown promise in the detection of premalignant airway lesions, each by utilizing different bandwidths of lights for better characterization of the mucosal and submucosal vascular grid. Since previously published meta-analyses have shown ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,meta分析

    doi:10.1177/1753465815589698

    authors: Iftikhar IH,Musani AI

    更新日期:2015-10-01 00:00:00